<DOC>
	<DOCNO>NCT01918358</DOCNO>
	<brief_summary>To compare safety pharmacokinetics ROVATITAN tab . 160/20 mg ( ROVATITAN tab 160/20mg-1 , ROVATITAN tab . 160/20mg-2 ) coadministration Diovan® ( Valsartan ) 160 mg Crestor® ( Rosuvastatin ) 20 mg healthy male volunteer</brief_summary>
	<brief_title>Safety Pharmacokinetics Between Fixed-dose Combination VR 160/20 mg Co-administration Diovan® ( Valsartan ) Film-coated Tablet 160 mg Crestor® ( Rosuvastatin ) 20 mg</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>1 . Healthy male age 20~45 year screen 2 . 19 kg/m2 ≤ BMI ≤27 kg/m2 screen 3 . Subject able communicate investigator understand nature clinical study willing able provide write informed consent form 1 . Subject current previous clinically significant disease liver , renal , neurologic , pulmonary , gastrointestinal , endocrine , hematologic , oncologic , cardiovascular , psychological , musculoskeletal system 2 . Patient renal defect ( Calculated GFR &lt; 60 ml/min base serum creatinine level ) 3 . Subject satisfy follow criterion sit blood pressure screen test 90 ≤SBP &lt; 140 ( mmHg ) 60 ≤ DBP &lt; 90 ( mmHg ) 4 . Subject satisfy follow criterion screen 1 ) AST ALT ≤ 1.5x ULN 2 ) Serum total bilirubin ≤ 1.5x ULN 3 ) CK ( Creatinine kinase ) ≤ 2x ULN 5 . Subject medical history gastrointestinal disease ( e.g. , Crohn 's disease , ulcer ) surgery ( appendicitis hernia repair allow ) might affect investigational product absorption 6 . Subject hypersensitivity drug contain component valsartan rosuvastatin drug ( aspirin , antibiotic ) previous clinically significant history hypersensitivity 7 . Subject previous history drug overdose positive drug ( Barbiturate , Benzodiazepine , Methamphetamine , Cannabinoids , Cocaine , Opiate ) urine drug screen test 8 . Subject take prescribed medicine oriental medicine within two week first investigational product administration , take overthecounter drug within one week first investigational product administration ( If subject eligible criterion , may participate clinical study base investigator 's discretion . ) 9 . Subject take investigational product within 60 day first investigational product administration 10 . Subject donated whole blood within 60 day donate apheresis blood within 30 day receive transfusion within 30 day first investigational product administaration . 11 . Subject take drug induce inhibit drugmetabolizing enzyme barbiturate within 30 day first investigational product administration 12 . Subject daily intake drink contain caffeine ( coffee , tea , coke ) grapefruit juice &gt; average 4 cup / day ( 800 mL ) subject discontinue drink clinical study period ( screen poststudy visit ) 13 . Subject mean weekly drinking amount &gt; 140g subject stop drinking outpatient visit investigational product administration , include hospitalization period . 14 . Subject mean daily smoking amount &gt; 10 cigarette subject stop smoking hospitalization 15 . Subject positive result serology test ( hepatitis B , hepatitis C , HIV ) 16 . Subject genetic muscle disease , familial history muscle disease , medical history drugderived muscle disorder 17 . Subject consider eligible investigator 's discretion .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>